JP7818011B2 - Ｍａｌｔ１モジュレーターおよびその使用 - Google Patents

Ｍａｌｔ１モジュレーターおよびその使用

Info

Publication number
JP7818011B2
JP7818011B2 JP2023548534A JP2023548534A JP7818011B2 JP 7818011 B2 JP7818011 B2 JP 7818011B2 JP 2023548534 A JP2023548534 A JP 2023548534A JP 2023548534 A JP2023548534 A JP 2023548534A JP 7818011 B2 JP7818011 B2 JP 7818011B2
Authority
JP
Japan
Prior art keywords
compound
trifluoroethyl
alkyl
μmol
triazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023548534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552002A5 (https=
JP2023552002A (ja
Inventor
ブライアン アディソン デクリストファー，
ギヨーム バルブ，
Original Assignee
レラファイド バイオサイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レラファイド バイオサイエンシーズ， インコーポレイテッド filed Critical レラファイド バイオサイエンシーズ， インコーポレイテッド
Publication of JP2023552002A publication Critical patent/JP2023552002A/ja
Publication of JP2023552002A5 publication Critical patent/JP2023552002A5/ja
Application granted granted Critical
Publication of JP7818011B2 publication Critical patent/JP7818011B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Escalators And Moving Walkways (AREA)
  • Inspection Of Paper Currency And Valuable Securities (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
JP2023548534A 2020-10-16 2021-10-15 Ｍａｌｔ１モジュレーターおよびその使用 Active JP7818011B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063092768P 2020-10-16 2020-10-16
US63/092,768 2020-10-16
PCT/US2021/055173 WO2022081967A1 (en) 2020-10-16 2021-10-15 Malt1 modulators and uses thereof

Publications (3)

Publication Number Publication Date
JP2023552002A JP2023552002A (ja) 2023-12-13
JP2023552002A5 JP2023552002A5 (https=) 2024-09-13
JP7818011B2 true JP7818011B2 (ja) 2026-02-19

Family

ID=81209361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548534A Active JP7818011B2 (ja) 2020-10-16 2021-10-15 Ｍａｌｔ１モジュレーターおよびその使用

Country Status (7)

Country Link
US (1) US20230391781A1 (https=)
EP (1) EP4228647A4 (https=)
JP (1) JP7818011B2 (https=)
CN (1) CN116916924B (https=)
AU (1) AU2021361057A1 (https=)
CA (1) CA3198715A1 (https=)
WO (1) WO2022081967A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202018412D0 (en) * 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
EP4638458A1 (en) * 2022-12-23 2025-10-29 Janssen Pharmaceutica NV Malt1 inhibitors
WO2024182599A2 (en) * 2023-03-01 2024-09-06 Rarefied Biosciences, Inc. Compositions and methods for treating malt1 associated diseases
WO2025223516A1 (zh) * 2024-04-24 2025-10-30 首药控股(北京)股份有限公司 一种抑制剂杂环化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017516778A (ja) 2014-05-28 2017-06-22 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびｍａｌｔ１阻害剤としてのその使用
WO2020111087A1 (ja) 2018-11-28 2020-06-04 武田薬品工業株式会社 複素環化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5593996A (en) * 1991-12-30 1997-01-14 American Cyanamid Company Triazolopyrimidine derivatives
EP1644003A1 (en) * 2003-06-04 2006-04-12 Vernalis (Cambridge) Limited Triazolo ´1,5-a!pyrimidines and their use in medicine
WO2008065198A1 (en) * 2006-12-01 2008-06-05 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
WO2017000277A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
US10711036B2 (en) * 2015-08-28 2020-07-14 Cornell University MALT1 inhibitors and uses thereof
PE20190656A1 (es) * 2016-07-29 2019-05-08 Lupin Ltd Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3810609B1 (en) 2018-06-18 2024-06-12 Janssen Pharmaceutica NV Pyrazole derivatives as malt1 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017516778A (ja) 2014-05-28 2017-06-22 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびｍａｌｔ１阻害剤としてのその使用
WO2020111087A1 (ja) 2018-11-28 2020-06-04 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
EP4228647A4 (en) 2024-09-11
EP4228647A1 (en) 2023-08-23
CA3198715A1 (en) 2022-04-21
AU2021361057A1 (en) 2023-06-08
AU2021361057A9 (en) 2025-03-20
CN116916924A (zh) 2023-10-20
CN116916924B (zh) 2026-02-27
US20230391781A1 (en) 2023-12-07
WO2022081967A1 (en) 2022-04-21
JP2023552002A (ja) 2023-12-13

Similar Documents

Publication Publication Date Title
JP7818011B2 (ja) Ｍａｌｔ１モジュレーターおよびその使用
EP3761980B1 (en) Amino acid compounds and methods of use
WO2021225912A1 (en) Treatment of respiratory diseases with amino acid compounds
EP4259631A1 (en) Imidazopyridazine derivatives as il-17 modulators
WO2022081995A1 (en) Malt1 modulators and uses thereof
US12286443B2 (en) Bycyclic JAK inhibitors and uses thereof
CN116194103B (zh) 细胞周期蛋白依赖性激酶7（cdk7）非共价抑制剂
WO2024015340A1 (en) Cereblon ligands and uses thereof
CN116583285B (zh) N-(咪唑并[1,2-b]哒嗪-3-基)-1-环己基-2H-吲唑-5-甲酰胺和N-(吡唑并[1,5-a]嘧啶-3-基)-1-环己基-2H-吲唑-5-甲酰胺衍生物作为IRAK4抑制剂用于治疗哮喘
JP2026510921A (ja) Ｎｌｒｐ３を阻害するためのアミド誘導体及びその使用
EP4499611B1 (en) Malt1 modulators and uses thereof
JP2024532729A (ja) フェロトーシス調節物質、その調製及び使用
CA3247233A1 (en) T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND THEIR METHODS OF USE
WO2024187066A1 (en) Compounds and compositions as cbp/p300 degraders and uses thereof
JP2025539264A (ja) ｅＩＦ４Ｅ阻害剤としての化合物及び組成物、ならびにそれらの使用
JP2025529836A (ja) 皮膚疾患の局所的処置のためのｊａｋ１／ｊａｋ２／ｔｙｋ２阻害剤
WO2025155786A1 (en) Bicyclic tyrosine kinase 2 inhibitors and uses thereof
EP4514779A1 (en) Kcnt1 inhibitors comprising a pyrazole core and methods of use
EA045845B1 (ru) Противовирусные средства для лечения и профилактики вич-инфекции

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240904

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260206

R150 Certificate of patent or registration of utility model

Ref document number: 7818011

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150